BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12881391)

  • 1. Phase II study of flavopiridol in patients with advanced colorectal cancer.
    Aklilu M; Kindler HL; Donehower RC; Mani S; Vokes EE
    Ann Oncol; 2003 Aug; 14(8):1270-3. PubMed ID: 12881391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
    Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
    J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
    Van Veldhuizen PJ; Faulkner JR; Lara PN; Gumerlock PH; Goodwin JW; Dakhil SR; Gross HM; Flanigan RC; Crawford ED;
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):39-45. PubMed ID: 15791454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
    Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
    Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
    Dickson MA; Shah MA; Rathkopf D; Tse A; Carvajal RD; Wu N; Lefkowitz RA; Gonen M; Cane LM; Dials HJ; Schwartz GK
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1113-21. PubMed ID: 20953860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Kouroukis CT; Belch A; Crump M; Eisenhauer E; Gascoyne RD; Meyer R; Lohmann R; Lopez P; Powers J; Turner R; Connors JM;
    J Clin Oncol; 2003 May; 21(9):1740-5. PubMed ID: 12735303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
    Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
    J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma.
    Burdette-Radoux S; Tozer RG; Lohmann RC; Quirt I; Ernst DS; Walsh W; Wainman N; Colevas AD; Eisenhauer EA
    Invest New Drugs; 2004 Aug; 22(3):315-22. PubMed ID: 15122079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
    Shah MA; Kortmansky J; Motwani M; Drobnjak M; Gonen M; Yi S; Weyerbacher A; Cordon-Cardo C; Lefkowitz R; Brenner B; O'Reilly E; Saltz L; Tong W; Kelsen DP; Schwartz GK
    Clin Cancer Res; 2005 May; 11(10):3836-45. PubMed ID: 15897584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
    Ramaswamy B; Phelps MA; Baiocchi R; Bekaii-Saab T; Ni W; Lai JP; Wolfson A; Lustberg ME; Wei L; Wilkins D; Campbell A; Arbogast D; Doyle A; Byrd JC; Grever MR; Shah MH
    Invest New Drugs; 2012 Apr; 30(2):629-38. PubMed ID: 20938713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.
    Flinn IW; Byrd JC; Bartlett N; Kipps T; Gribben J; Thomas D; Larson RA; Rai K; Petric R; Ramon-Suerez J; Gabrilove J; Grever MR
    Leuk Res; 2005 Nov; 29(11):1253-7. PubMed ID: 15916806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
    Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M; Broering S; Schaaf LJ; Johnson AJ; Lucas DM; Heerema NA; Lozanski G; Young DC; Suarez JR; Colevas AD; Grever MR
    Blood; 2007 Jan; 109(2):399-404. PubMed ID: 17003373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
    Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.
    George S; Kasimis BS; Cogswell J; Schwarzenberger P; Shapiro GI; Fidias P; Bukowski RM
    Clin Lung Cancer; 2008 May; 9(3):160-5. PubMed ID: 18621626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
    Liu G; Gandara DR; Lara PN; Raghavan D; Doroshow JH; Twardowski P; Kantoff P; Oh W; Kim K; Wilding G
    Clin Cancer Res; 2004 Feb; 10(3):924-8. PubMed ID: 14871968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
    Bible KC; Lensing JL; Nelson SA; Lee YK; Reid JM; Ames MM; Isham CR; Piens J; Rubin SL; Rubin J; Kaufmann SH; Atherton PJ; Sloan JA; Daiss MK; Adjei AA; Erlichman C
    Clin Cancer Res; 2005 Aug; 11(16):5935-41. PubMed ID: 16115936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.
    Glimelius B; Ristamäki R; Kjaer M; Pfeiffer P; Skovsgaard T; Tveit KM; Linné T; Frödin JE; Boussard B; Oulid-Aïssa D; Pyrhönen S
    Ann Oncol; 2002 Dec; 13(12):1868-73. PubMed ID: 12453854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
    Stadler WM; Vogelzang NJ; Amato R; Sosman J; Taber D; Liebowitz D; Vokes EE
    J Clin Oncol; 2000 Jan; 18(2):371-5. PubMed ID: 10637252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
    Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
    J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.